Extended-Release Oxycodone Efficacious for Chronic Low Back Pain – Clinical Pain Advisor

PAINWeek– Abuse-deterrent extended-release oxycodone (Xtampza® ER; Collegium Pharmaceutical) provided adequate pain relief for patients with chronic low back pain who were previously receiving immediate-release oxycodone, according to research presented at PAINWeek 2017, held September 5-9, in Las Vegas, Nevada.

In a post hoc analysis of a phase 3 efficacy and safety study of the abuse-deterrent oxycodone ER, researchers evaluated the (more…)

Study examines public health impact of tamper resistant extended-release … -…

This is the first epidemiological study to examine the public health impact of a tamper resistant extended-release oxycodone (ORF). ER oxycodone was reformulated with physicochemical barriers to crushing and dissolving intended to reduce abuse through non-oral routes of administration. Manufacturer shipments of original ER oxycodone stopped on August 5, 2010, and ORF shipments started August 9, 2010. During the first 20 (more…)

Study finds reformulated ER Oxycodone abuse rates are significantly lower than … -…

  • Aims of this study were to assess 1) whether the rates of abuse of extended-release (ER) oxycodone (OxyContin®) decline following introduction of reformulated ER oxycodone (ORF), and 2) whether ORF is less likely to be abused through non-oral routes of administration that require tampering
  • Researchers obtained data from 140,496 individuals assessed for substance abuse treatment at 357 treatment centers
  • Findings were consistent with (more…)